Weighed Down by 13% in One Month, Ipsen Stock Declines Further Following Jefferies Downgrade
The Parisian biopharmaceutical laboratory resumes its downward trend in a declining Paris market. A London research firm has recently hardened its view, at a time when the stock is trading below all of its moving averages.
Jefferies Downgrades to Underperform and Lowers Price Target to 130 Euros
The Ipsen share fell 1.86% to 142.30 € during the session, in the lower part of the SBF 120, as the index declined 0.77%. Jefferies published today an analyst rating at "underperform", with a price target reduced from 135 € to 130 €. This target is 8.6% below the current price.
The stock has lost 13.1% over one month and 15.5% over three months. It had plunged more than 7% on September 22, following U.S. authorization of a generic version of lanreotide, the active ingredient in Somatuline, produced by Amneal. This competitor's arrival is among the risks cited by the company during its H1 2026 results publication on July 30.
Stock Price Below Its Three Moving Averages, 1.3 € Away from the 140.50 € Support Level
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The price is below the 20-day MA (deviation of -4.45%), the 50-day MA (-9.14%) and the 200-day MA (-7.84%). The 140.50 € support level is less than 1.3% away from the current price: it had been breached on October 5 during the session before being recovered. The RSI at 40 shows neither overbought nor oversold conditions.
During the H1 2026 results publication on July 30, Ipsen had raised its financial targets for the fiscal year and highlighted the positive Phase III results of Dysport in migraine. Based on expected earnings per share, the stock is trading at approximately 9.4 times the earnings of the current fiscal year, according to the consensus of surveyed analysts. The 140.50 € level remains the closest technical reference point.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 2 190 millions d'euros
Quarterly revenue: 2 190 millions d'euros
Revenue growth: 20,4 %
EBITDA: 733,9 millions d'euros
EBITDA margin: 40,7 %
Net income: 403,1 millions d'euros
Free cash flow: 651,7 millions d'euros
-1 005 millions d'euros
Guidance from the release
Cette dynamique nous permet de relever nos objectifs financiers pour 2026
Risks mentioned
Arrivée potentielle de génériques du lanréotide, concurrençant les ventes de Somatuline
Effet défavorable des devises d'environ 1 % anticipé sur l'exercice 2026
Impact dilutif des acquisitions de Memo Therapeutics AG et de Kartos Therapeutics sur la marge
Opportunities identified
Plusieurs lancements attendus à court terme d'actifs à potentiel de blockbuster dans les trois aires thérapeutiques
Résultats positifs de Phase III de Dysport dans la migraine épisodique et chronique
Résultats positifs de Phase IIIb ELSPIRE d'Iqirvo dans la cholangite biliaire primitive
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
